1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
TTY Biopharm Company Limited

TTY Biopharm Company Limited

TTPEX:4105
80.60
TWD
-0.40
(-0.49%)
18.82BMarket Cap
Oct 30Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
13.35
11.98
12.85
15.12
16.4
16.23
17.96
16.98
18.24
20.36
22.14
23.7
25.95
- -
Basic EPS, GAAP
2.52
3.14
4.87
4.8
5.41
5.88
3.62
3.72
3.35
4.4
4.54
5.83
6.27
- -
Free Cash Flow per Basic Share
0.21
-0.44
1.83
4.52
3.62
3.97
4.58
1.39
4.75
4.42
3.96
4.89
6.48
- -
Dividend per Share
1.29
1.87
2.5
3.5
3.8
4.5
4.5
4
4
3
3.4
3.5
4.2
-0.14
Book Value per Share
15.59
16.87
20.52
21.63
22.11
23.34
22.4
21.92
20.78
22.76
23.89
27.15
29.11
27.97
Tangible Book Value per Share
15.24
16.61
20.31
21.51
21.53
22.73
21.84
21.38
20.28
21.75
23.23
25.65
27.4
25.66
Basic Weighted Avg Shares
233
249
249
249
249
249
249
249
249
249
249
249
249
249
Sales/Revenue/Turnover
3,110
2,980
3,195
3,761
4,079
4,036
4,466
4,222
4,536
5,062
5,506
5,894
6,453
- -
Operating Margin (%)
10.93
11.35
24.72
31.37
30.82
26.11
27.39
22.62
25.48
24.34
24.98
23.65
26.42
- -
Depreciation Expense
102
124
119
123
141
146
152
157
167
186
201
202
197
- -
Net Income, GAAP
587
780
1,211
1,193
1,345
1,461
900
924
832
1,094
1,129
1,450
1,559
- -
Effective Tax Rate (%)
22.93
10.79
18.29
17.02
14.22
12.34
24.52
18.55
24.35
21.67
21.2
19.43
22.14
- -
Profit Margin (%)
18.89
26.16
37.9
31.73
32.97
36.21
20.15
21.89
18.34
21.62
20.5
24.6
24.16
- -
Working Capital
503
161
2,232
2,388
2,214
2,683
1,949
2,250
1,698
2,118
2,787
2,931
3,369
3,414
LT Debt
- -
- -
700
630
250
350
16
412
18
13
403
110
7
405
Total Equity
4,328
4,632
5,695
6,010
6,112
6,392
6,169
6,078
5,767
6,233
6,506
7,511
8,051
7,749
Return on Invested Capital (%)
4.33
4.8
9.02
12.15
12.83
11.24
11.62
9.65
10.56
11.83
12.98
12.53
13.99
- -
Return on Capital (%)
9.08
12.38
17.08
14.64
16.3
18.14
11.55
11.09
10.56
13.74
14.12
15.95
16.1
- -
Return on Common Equity (%)
15.97
19.32
26.05
22.77
24.73
25.86
15.83
16.77
15.67
20.22
19.46
22.84
22.29
- -

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,218
1,028
1,660
LT Borrowings
- -
- -
400
LT Finance Leases
7
6
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
249
249
249
Market Capitalization
20,265
18,102
18,823

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
6,009
6,187
6,430
Cash, Cash Equivalents & STI
2,989
3,307
3,377
Accounts Receivable, Net
1,495
1,328
1,375
Inventories
1,389
1,406
1,392
Total Current Liabilities
2,640
3,621
3,017
Payables & Accruals
- -
- -
- -
ST Debt
1,218
1,028
1,660
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.68%
6%
7.19%
Free Cash Flow
36.45%
56.34%
32.58%
Net Income, GAAP
4.48%
12.14%
7.55%
Sales/Revenue/Turnover
7.46%
8.87%
9.49%
Total Cash Common Dividend
- -
- -
20%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,274
1,375
1,533
1,712
5,894
2025
1,459
1,512
- -
1,662
6,453
2026
1,520
1,652
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.13
1.05
1.5
2.15
5.83
2025
1.57
1.14
- -
1.22
6.27
2026
1.78
1.63
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.09
-0.09
3.5
2025
- -
- -
- -
-0.14
4.2
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ching Lan Hou
Full Time Employees
517
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No.3-1, Park Street Taipei TP Taiwan 11503
IPO Date
Sep 27, 2001
Website
tty.com.tw
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
TTY Biopharm Company Limited, along with its associated entities, specializes in the research, development, manufacturing, and commercialization of advanced pharmaceutical and chemical products across Taiwan and international markets. The enterprise is structured around key operational divisions, including its Oncology Business, Intensive Care Business, Healthcare Business, and an Export and Contract Development and Manufacturing Organization (CDMO) Business. The company delivers a diverse portfolio of oncology medications, encompassing anti-cancer therapies and supportive care treatments. In the anti-infection realm, it offers critical anti-infective agents and influenza vaccines, such as the recently launched antibiotic, Bobimixyn. Furthermore, TTY Biopharm provides a range of healthcare-focused products addressing digestive health, bone density, and metabolic conditions. Key offerings also include innovative drugs developed using advanced liposome and microsphere technologies, such as Lipo-AB, which is expanding in the U.S. market, and the blood cancer therapy Minjuvi, approved in early 2025. Beyond its core pharmaceutical lines, the company is actively involved in the sale of functional foods and undertakes global import and export trade, alongside strategic investment activities. TTY Biopharm leverages its robust research and development capabilities to create specialized formulations and novel drugs, aiming to address unmet medical needs. The company reported strong financial results for the third quarter and nine months ended September 30, 2025, with increased sales and net income. Established in 1960, TTY Biopharm Company Limited maintains its headquarters in Taipei, Taiwan.